A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
News Zimmer bets on autonomous surgery with Monogram purchaseHealthradar16. Juli 2025 Zimmer Biomet hopes to round out its surgical robotics portfolio with its planned $177 million purchase of Monogram Technologies, which…
